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diabetics 30%) with CTO treated with BVS were enrolled. A total of 63
BVS were implanted with the average number of 1.6 per patient, and
the scaffold length of 42.4  21.5 mm. Mean J-CTO score was 1.6.
Antegrade approach was used in 38 patients (95%), and retrograde,
after failed antegrade, in the remaining two (5%). High pressure post-
dilatation was performed in 38 patients. Procedural success was
achieved in all patients with no device-related complications. IVUS
was used in two, whereas OCT in ten patients. On QCA the mean in-
scaffold ﬁnal MLD was 2.13  0.31 mm and residual stenosis 13.90 
7.59%. In OCT analysis, performed in 10 patients, the minimal in-
scaffold luminal diameter was 2.65  0.45 mm, minimal luminal area
6.15  0.20 mm2, and lumen area stenosis 17.7  11.1%. At follow-up
(median time 434 days), there were no deaths, one patient experi-
enced subacute and late scaffold thrombosis (ST), another one
developed symptomatic in-scaffold focal restenosis treated with
repeat PCI. At control angiography, performed at the median time of
264 days in 23 patients (58%), the mean in-scaffold diameter stenosis
was 22.42  12.74, and the mean late lumen loss was 0.24  0.55 mm.
No more restenosis or vessel reocclusion was found.
CONCLUSIONS Stenting of coronary CTO lesions with bioresorbable
everolimus-eluting scaffolds is feasible with excellent acute perfor-
mance and good early and long-term clinical outcomes. Adequate
stenting technique and optimal DAPT is of crucial importance. The
results of our study represent a major step forward towards more
complete implementation of BVS to coronary interventions.
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BACKGROUND The bioresorbable vascular scaffold (BVS) is a new
therapy that provides transient vessel support with drug delivery
capability, potentially without the limitations of permanent metallic
implants. It can be an alternative option to currently used drug eluting
stents (DES) for percutaneous coronary intervention (PCI) of ischemic
coronary artery disease (CAD). We aimed to compare the non-inferi-
ority of BVS use to DES.
METHODS We searched Pub Med and Cochrane through June 2015 for
all randomized clinical trials (RCTs) that directly compared BVS and
DES for ischemic CAD. Primary outcome was target vessel revascu-
larization (TVR). Secondary outcomes included cardiac death, acute
myocardial infarction, and deﬁnite or probable stent thrombosis (ST).
We used Fixed or Random Effect analysis using the Cochrane Hand-
book of Systematic Reviews and RevMan 5.2 for statistical analysis.
RESULTS Out of 257 articles, four randomized trial studies were
included. The pooled data provided 3873 patients; 2024 treated with
BVS and 1849 with Everolimus drug-eluting stent. Mean follow up was
12 months. There was a trend towards lower TVR in BVS group
compared to Everolimus group (2.7% vs. 4.5%, p¼0.1) (Figure 1). There
was no difference in cardiac death (0.7 % vs. 0.7%, p¼0.8), AMI (3.4%
vs. 3.4%, p¼0.9) and ST (0.6% vs. 0.7%, p¼0.9) between the two
groups (Figure 2).CONCLUSIONS Our analysis showed similar outcomes between two
treatment modalities. This suggests that BVS might not be inferior to
DES for PCI of ischemic CAD. Further randomized trials should be
pursued to conﬁrm those ﬁndings.
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BACKGROUND Bioresorbable scaffolds (BRS) are an attractive option
for the percutaneous treatment of coronary artery disease due to the
potential advantages associated with its complete absorption within
3-4 years of implantation. However, due the current design of BRS
with thicker struts compared to contemporary metallic stents, some
concern remains that this property may be associated with adverse
events including thrombosis and restenosis when using small BRS.
METHODS Among 350 consecutive lesions treated with Absorb BRS
during May 2012 – Apr 2015 at 2 high volume centers in Milan, 116
lesions were treated using 2.5 mm BRS (small BRS group) and 234
lesions were treated with BRS >2.5 mm BRS (large BRS group). Out-
comes including target lesion revascularization (TLR) per lesion and
deﬁnite stent thrombosis were investigated.
RESULTS The number of BRS was higher and the total BRS length was
longer in the small BRS group when compared to the large BRS group
(1.7  0.8 vs 1.4  0.6; p<0.001, and 42.3  22.6 mm vs 30.7  15.0mm;
p<0.001, respectively). As expected, the post procedural minimum
lumen diameter was signiﬁcantly smaller in the small BRS group (2.36
 0.43mm vs 2.82  0.44mm; p<0.001). TLR- free rate (median
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between the two groups (p¼0.59). One-year TLR free rate was 95.7 
2.1% in the small BRS group and 92.5  2.1% in the large BRS group.
There were no differences between groups with regards to deﬁnite
stent thrombosis with was 1 late thrombosis in the small BRS group
and 1 acute thrombosis in the large BRS group.
CONCLUSIONS Percutaneous coronary intervention using small BRS
was associated with comparable outcomes when compared to larger
BRS with no observed increase in adverse events.
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BACKGROUND This in-vivo study sought to provide insights
regarding the feasibility and safety of performing complex bifurcation
techniques with the Absorb everolimus-eluting bioresorbable vascular
scaffold (BVS, Abbott Vascular, Santa Clara, US).
METHODS Twenty Adult New Zeeland white rabbits were anaes-
thetized and a long 6 Fr arterial sheath was placed in the carotid artery
extending to the distal aorta. Heparin was administered. Bifurcation
stenting procedures of the aorta-iliac bifurcation (70 angle) were
performed with 3.0x28 mm BVS using the following techniques: main-
vessel (MV) stenting with ballooning of side branch (SB) through the
BVS struts (Provisional stenting, n¼5), T-and protrusion (TAP, n¼5),
modiﬁed T (n¼5) and culotte (n¼5) stenting. Proximal optimization
technique with 3.5 mm non-compliant (NC) balloons at 16 atm and
mini-kissing balloon post-dilatation with 3.0 NC balloons at 5 atm
were performed in all procedures. Angiography, optical coherence
tomography (OCT) and post-procedural micro-computed tomography
(micro-CT) were performed.
RESULTS In all procedures angiographic results were excellent with
no evidence of dissection or SB compromise. Re-crossing through BVS
struts with guidewires and balloons þ/- second BVS (TAP þ culotte
procedures) was smooth. Provisional stenting optimally opened the
SB ostium without deforming the BVS. On OCT there was no malap-
position and micro-CT revealed good SB aperture and a single
connector fracture was present in the MV in 1 of the 5 cases. Modiﬁed
T stenting (SB stented ﬁrst, n¼5) and TAP stenting (MV stented ﬁrst,
n¼5) resulted in complete coverage of the SB ostium and carina. In
both techniques no signiﬁcant malapposition was present. On Micro-
CT, no strut fractures were present following modiﬁed T stenting,
whilst in 3 out of 5 TAP procedures single strut fractures were noted,
these did not cause luminal compromise. Culotte stenting (n¼5)
resulted in complete coverage of the bifurcation with an extensive
proximal segment of double-layered scaffold struts. In 3 of the 5
culotte procedures, OCT revealed signiﬁcant circumferential malap-
position at the level of the bifurcation. On micro-CT there was
distortion of MV and SB scaffolds at the level of the bifurcation with
single strut fractures present in all 5 cases. These fractures did not
cause luminal compromise.
CONCLUSIONS In this non-diseased in-vivo aorta-iliac bifurcation
model, it was feasible to perform complex bifurcation stenting using
Absorb BVS with excellent angiographic results. Provisional stenting
with additional TAP stenting seems a reasonable standard approach
for most bifurcation lesions. When a 2-stent technique is planned
from the outset, modiﬁed T-stenting was the most promising with no
evidence of signiﬁcant malapposition or scaffold disruption on OCT
and micro-CT, respectively. Finally, culotte stenting frequently
caused signiﬁcant circumferential malapposition, scaffold distortion
and strut fractures, the clinical impact of which is unknown.
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BACKGROUND Multiple studies have proven safety and feasibility of
the BVS bioresorbable scaffold. However, most of these studies were
restricted by rather non-complex lesions or short follow-up.
METHODS This is an investigator initiated, prospective, mono-center,
single-arm study. Inclusion criteria were patients presenting with
NSTEMI, stable, unstable angina, or silent ischemia caused by a de
novo stenotic lesion in a native previous untreated coronary artery.
Lesions with a Dmax (proximal and distal mean lumen diameter)
within the upper limit of 3.8 mm and the lower limit of 2.0 mm by
online QCA were obligatory. Exclusion criteria were patients with a
history of CABG, presentation with cardiogenic shock, bifurcation le-
sions requiring kissing balloon post-dilatation, STEMI patients
requiring immediate stent implantation, allergies or contra-in-
dications to antiplatelet therapy, female patient with child bearing
potential not taking adequate contraceptives or currently breast-
feeding, expected survival of less than one year. Procedural outcomes
and clinical outcomes were assessed.
RESULTS From September 2012 to January 2015, 250 patients with 335
lesions were enrolled in this study. A total of 445 BVS were placed
with a mean number of implanted scaffolds/ patient of 1.37. Pre-
dilatation was performed in 89.8%. Predilatation balloon: artery ratio
was 1.050.23. Post-dilatation was performed in 54.3%. In 14.5%
baseline imaging using IVUS was used; OCT in 24.9%. Bifurcation was
present in 21.4%, calciﬁcation in 42.2% and total occlusions in 4.2%.
In 38.0% there were AHA classiﬁcation type B2/ C lesions. Mean lesion
length was 22.1013.90 mm. Pre-procedural reference vessel diameter
(RVD) was 2.420.74mm, minimal lumen diameter (MLD)
0.910.45mm and percentage diameter stenosis (%DS) 59.13 0.72.
Post-procedural QCA characteristics were as followed: RVD
2.770.46 mm, MLD 2.300.42 mm and %DS 16.909.04. Median
follow-up period was 559 days (interquartile range [IQR], 371-733
days). Up to 12 months three patients died (all cardiac death) with a
Kaplan Meier estimate of 1.4% at one year. Rate of all myocardial
infarction (MI) was 4.1%, deﬁnite scaffold thrombosis (ST) 1.4%, target
lesion revascularization (TLR) and target vessel revascularization
(TVR) were 3.7%. Non-target vessel revascularization (non-TVR) was
3.8%. Major cardiac adverse events (MACE, a composite endpoint of
cardiac death, TLR and all MI) at one year was 5.5%.
CONCLUSIONS Long-term results in a mixed group of patients imply
that BVS usage is associated with favorable clinical outcomes.
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BACKGROUND While Bioresorbable Vascular Scaffolds (BVS) are
increasingly used in clinical practice, behavior when post-dilated
beyond their recommended maximum over-expansion diameter re-
mains sparsely documented.
METHODS We examined the post-expansion behavior of the Bio-
resorbable Vascular Scaffold (3.0mm and 3.5mm Absorb BVS; Abbott
Vascular, Santa Clara, CA) after over-expansion with Non-Compliant
(NC) balloons of increasing diameters. After each oversizing step, the
scaffolds were measured and inspected for strut disruption using
